Gastroesophageal Reflux Disease (GERD) Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The gastroesophageal reflux disease (GERD) market size has grown marginally in recent years. It will grow from $5.25 billion in 2024 to $5.35 billion in 2025 at a compound annual growth rate (CAGR) of 2%. The growth in the historic period can be attributed to lifestyle and dietary changes, obesity epidemic, growing awareness about gerd treatment, globalization of pharmaceutical industry, investments for gerd treatments.

The gastroesophageal reflux disease (GERD) market size is expected to see steady growth in the next few years. It will grow to $5.94 billion in 2029 at a compound annual growth rate (CAGR) of 2.7%. The growth in the forecast period can be attributed to aging population, rising healthcare spending, emergence of biomarker, growing number of screening programs for gerd, increasing prevalence of heartburn, increased demand for medical equipment. Major trends in the forecast period include diagnostic advancements, surgical advancements, development of targeted therapies, adoption of telehealth services.

The high incidence of alcohol consumption is expected to drive the growth of the gastroesophageal reflux disease (GERD) market. Alcohol consumption refers to the ingestion of beverages containing ethanol, which, when consumed in excess, can contribute to the development of GERD by reducing esophageal motility and lowering the pressure levels in the esophagus. For example, in July 2024, the House of Commons Library, a UK-based institution, reported that in 2022, 56% of adults in England had consumed alcohol in the past week. This data revealed a gender difference in drinking habits, with 61% of men and 51% of women having consumed alcohol during this period. Consequently, the increasing prevalence of alcohol consumption is fueling the growth of the GERD market.

Prominent companies operating in the gastroesophageal reflux disease (GERD) market are dedicated to the introduction of innovative treatment devices for GERD, aimed at maintaining their market leadership. For example, in April 2023, Laborie Medical Technologies, a US-based medical technology firm, unveiled the alpHaONE wireless pH-capsule reflux testing diagnostic system, designed specifically for the diagnosis of gastroesophageal reflux disease (GERD). This advanced system is capable of providing up to 96 hours of comprehensive monitoring data. Notably, it boasts a compact and user-friendly design with conveniently enlarged buttons and a dependable capsule delivery system. Moreover, it features a dedicated software application equipped with a virtual instruction program and the option for users to customize symptom buttons, thereby enhancing the overall user experience. This innovative approach is significantly impacting the evolution of the GERD treatment market.

In October 2022, Sebela Pharmaceuticals Inc., a US-based pharmaceutical company specializing in the production of gastroesophageal reflux disease medications, established a strategic partnership with HK Inno.N Corporation, a South Korea-based pharmaceutical company, in an arrangement involving an undisclosed sum. This collaboration is aimed at jointly developing and launching tegoprazan, a pioneering potassium-competitive acid blocker (P-CAB), within the US and Canada. Tegoprazan, already authorized and available in South Korea and China, holds significant promise as an innovative addition to Sebela Pharmaceuticals' gastroenterology product line, catering to individuals dealing with gastroesophageal reflux disease.

Major companies operating in the gastroesophageal reflux disease (GERD) market are GlaxoSmithKline PLC, SRS Life Sciences, Johnson & Johnson Services Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Reckitt Benckiser Group PLC, Eisai Co. Ltd., Pfizer Inc., Medtronic PLC, Teva Pharmaceuticals, HK inno.N Corporation, Sebela Pharmaceuticals, Mylan N.V., Bausch Health Companies Inc., Johnson & Johnson MedTech, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Almirall S.A., HK inno.N Corporation, SRS Life Sciences Pte. Ltd.

North America was the largest region in the gastroesophageal reflux disease (GERD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastroesophageal reflux disease (GERD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastroesophageal reflux disease (GERD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastroesophageal reflux disease (GERD) market consists of revenues earned by entities by providing pharmaceutical therapies, surgical procedures and diagnostic tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastroesophageal reflux disease (GERD) market also includes sales of gamma-aminobutyric acid type B receptor agonists and alginate antacids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Gastroesophageal reflux disease (GERD) is a condition characterized by the regurgitation of stomach acid into the esophagus, leading to irritation and discomfort. Treating GERD involves employing a range of medical strategies and interventions to effectively manage its symptoms and associated complications.

The primary drug categories used in the treatment of gastroesophageal reflux disease include antacids, proton pump inhibitors, H2 receptor blockers, prokinetic agents, dopamine receptor antagonists, and minimally invasive procedures such as EndoCinch, Stretta, Asphyx, and Transoral Incisionless Fundoplication (TIF). Antacids, for instance, function by neutralizing stomach acid, thus increasing the stomach's pH level to alleviate symptoms. Additionally, these treatment approaches can be divided into invasive and minimally invasive procedures, offering options that cater to the unique needs of patients. These therapies are made available through various healthcare providers, including hospitals, homecare services, and specialty clinics.

The gastroesophageal reflux disease (GERD) market research report is one of a series of new reports that provides gastroesophageal reflux disease (GERD) market statistics, including gastroesophageal reflux disease (GERD) industry global market size, regional shares, competitors with a gastroesophageal reflux disease (GERD) market share, detailed gastroesophageal reflux disease (GERD) market segments, market trends and opportunities and any further data you may need to thrive in the gastroesophageal reflux disease (GERD) industry. This gastroesophageal reflux disease (GERD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.